News | November 04, 2007

Study Says Sirolimus-Eluting Stent Safety Similar to BMS at Five Years

November 5, 2007 - A pooled analysis of the E-SIRIUS and C-SIRIUS trials, called New SIRIUS, found that the CYPHER sirolimus-eluting coronary stent continued to provide clinical benefits with similar safety compared to a bare metal stent at five-year follow-up, according to data presented at the American Heart Association Scientific Session 2007.

At five-year follow-up, the patients in the CYPHER Stent arm of the New SIRIUS study continued to be significantly less likely than the patients in the bare metal stent arm to need another procedure in the same arterial area (target lesion revascularization). In addition, the investigators found similar rates of myocardial infarction (heart attack) and mortality with the CYPHER Stent and the bare metal stent, and no significant difference in the rates of stent thrombosis (blood clots).

According to the New SIRIUS analysis presented, patients who received a CYPHER Stent were less likely to require a second procedure - bypass surgery or percutaneous intervention - in the same arterial area within five years than a patient who was implanted with a bare metal stent. The five-year results demonstrated that 8.0 percent of the patients in the CYPHER Stent arm underwent another percutaneous procedure in the same arterial area, compared to 25.1 percent of the patients in the bare metal stent arm of the study (p

The New SIRIUS study also showed that both treatment arms yield similarly low rates of mortality and myocardial infarction. The mortality rates were 7.6 percent for the CYPHER Stent and 7.5 percent for the bare metal stent (p=1.00). The Q-wave myocardial infarction rate was 3.1 percent for the CYPHER Stent and 1.8 percent for the bare metal stent (p=0.38) and the non-Q-wave myocardial infarction rates were 7.6 percent for the CYPHER Stent and 5.7 percent for the bare metal stent (p=0.46).

The New SIRIUS study did not find a significant difference in the rates of stent thrombosis between the CYPHER Stent and the bare metal stent when using any of the Academic Research Consortium (ARC) definitions. The definite ARC definition yielded a stent thrombosis rate of 2.7 percent for the CYPHER Stent and 0.9 percent for the bare metal stent (p=0.174). The probable ARC definition identified a stent thrombosis rate of 1.3 percent for each treatment arm (p=1.000). The possible ARC definition provided a stent thrombosis rate of 2.2 percent for the CYPHER Stent versus 1.3 percent for the bare metal stent (p=0.502). The definite/probable/possible ARC definition yielded a stent thrombosis rate of 6.2 percent for the CYPHER Stent versus 3.5 percent for the bare metal stent (p=0.197).

The E-SIRIUS and C-SIRIUS trials are double-blind, multi-center, controlled, randomized trials designed to compare in-stent minimal lumen diameter and restenosis (re-blockage) rates between the CYPHER Stent and a bare metal stent. The E-SIRIUS trial involved 352 patients from 35 European clinical centers and the C-SIRIUS trial involved 100 patients from eight Canadian clinical centers. Cordis Corp. funded the New SIRIUS, C-SIRIUS and E-SIRIUS studies.

For more information: www.cypherstent.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init